Market Overview

According to fortune business insights, the global lupus nephritis drugs market size was valued at USD 1.90 billion in 2025. The market is projected to grow from USD 2.12 billion in 2026 to USD 4.64 billion by 2034, exhibiting a CAGR of 10.28% during the forecast period. Asia Pacific dominated the lupus nephritis drugs market with a market share of 48.42% in 2025.

The analysis shows that top companies are receiving new regulatory approvals as the focus on treating kidney involvement in lupus patients grows. For example, in June 2025, GSK plc received U.S. FDA approval for its Benlysta autoinjector for patients aged five and older, improving treatment convenience. This trend indicates strong demand for innovative and effective therapies worldwide.

Major Players Profiled in the Market Report:

  • GSK plc (U.K.)
  • Aurinia Pharmaceuticals Inc. (Canada)
  • Genentech, Inc. (U.S.)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Astellas Pharma Inc. (Japan)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)

Segments

Growing Adoption of Targeted B-Cell Therapies to Propel Monoclonal Antibody Segment Growth
Based on drug type, the market is divided into monoclonal antibody, immunosuppressant, and corticosteroids. The monoclonal antibody segment holds the largest market share and dominates the market owing to the increasing use of targeted B-cell therapies like belimumab in combination with conventional treatments.

High Disease Prevalence and Intensity to Drive Class 4 Segment Expansion
By disease type, the market is categorized into Class 3 (Focal), Class 4 (Diffuse), and Class 5 (Membranous). The Class 4 segment is leading the market as it is highly prevalent among patients and is associated with extensive kidney inflammation that requires intensive and prolonged treatment.

Established Use in Long-Term Therapy to Dominate Oral Route Segment
Based on route of administration, the market is segmented into oral and parenteral. The oral segment holds the largest market share owing to its practicality for the prolonged induction and maintenance therapy required for lupus nephritis, with core treatments like calcineurin inhibitors being administered orally.

Specialist-Led Treatment to Propel Hospital Pharmacy Segment Growth
Based on distribution channel, the market is split into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. The hospital pharmacies segment leads market growth as lupus nephritis is managed by hospital-based specialists who prescribe high-cost biologics and infusions.

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

For detailed market insights: https://www.fortunebusinessinsights.com/lupus-nephritis-drugs-market-119095

Report Coverage

The report offers:

  • Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
  • Comprehensive insights into regional developments.
  • List of major industry players.
  • Key strategies adopted by the market players.
  • The latest industry developments include product launches, partnerships, mergers, and acquisitions.

Drivers & Restraints

Increasing Adoption of Targeted Combination Therapy to Propel Market Growth
The rapid growth in the adoption of targeted combination therapies, which pair biologics with conventional immunosuppressants, has raised the standard of care. This approach improves renal response rates and reduces dependence on high-dose steroids, boosting the lupus nephritis drugs market growth.

However, the high cost of targeted biologics and calcineurin inhibitors, combined with restrictive reimbursement controls from payers, may hamper market growth by limiting patient access and delaying treatment initiation.

Regional Insights

Large Patient Population and Improving Diagnosis Propel Market Growth in Asia Pacific
Asia Pacific holds the dominant lupus nephritis drugs market share and is projected to experience strong growth during the forecast period. The region’s growth is attributed to a large susceptible patient population, improving diagnosis rates, and rising specialist-care capacity.

North America is another major market for lupus nephritis drugs. The market’s growth is supported by high disease awareness, established rheumatology-nephrology care networks, and broader use of advanced targeted combination therapies.

Lupus Nephritis Drugs Market Future Growth:

The lupus nephritis drugs market is experiencing robust growth, fueled by the rising adoption of targeted combination therapies, the growing trend of biomarker-guided precision treatment, and a strong shift toward steroid-sparing regimens. Today's treatment strategies are increasingly focused on achieving deeper and faster renal responses—favoring options like calcineurin inhibitors and B-cell targeting monoclonal antibodies that act on specific immune pathways. Additionally, there's a growing pipeline of next-generation therapies and an emphasis on improving patient convenience through new formulations. The expansion of regulatory approvals and improved access in emerging markets are also key growth drivers. While Asia Pacific holds a dominant market share, North America and Europe continue to be strong markets due to high treatment standards.

Competitive Landscape

Growing Focus on Regulatory Expansion and Targeted Product Development to Propel Market Growth
The market features prominent players like GSK, Aurinia Pharmaceuticals, and Roche/Genentech. These leading companies are accelerating growth through strategic initiatives such as securing new regulatory approvals, expanding product indications, generating long-term data to prove renal outcomes, and developing more convenient treatment options. Their proactive approach to incorporating targeted therapies into combination regimens continues to fuel the market’s momentum.

Key Industry Development

  • March 2026: Aurinia Pharmaceuticals Inc. acquired Kezar Life Sciences, Inc., gaining access to Zetomipzomib, an immunoproteasome inhibitor in development for lupus nephritis and other autoimmune diseases.
  • October 2025: Genentech Inc. received U.S. FDA approval for Gazyva (obinutuzumab) for the treatment of adult patients with active lupus nephritis, offering a twice-yearly infusion option after initial dosing.
  • November 2024: Adicet Bio, Inc. dosed its first patient in a Phase 1 trial for ADI-001, an investigational CAR-T cell therapy for lupus nephritis that has received FDA Fast Track Designation.

Uncover Japan’s Market Trends - Explore the Latest Lupus Nephritis Drugs Market Insights